Condition: Myeloproliferative Neoplasm · Sponsor: Wake Forest University Health Sciences
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
This description comes directly from the study's public registry record.
Courtney Schepel · (980) 292-0817 · Courtney.Schepel@atriumhealth.org
Always discuss trial participation with your own doctor first.
| Atrium Health Levine Cancer | Charlotte, North Carolina, United States | Recruiting |
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06480591